The use of atypical antipsychotics in patients with schizophrenia is tightly related to the metabolic abnormalities like weight gain, diabetes, dyslipidemia and/or hypertension. Beside of having unique receptor binding features, their heterogeneous receptor binding properties ara also involved in the occurence of the metabolic side effects caused by atypical antipsychotics. It is striking that atypical antipschotics related metabolic side effects have the potential to influence each other in a negative way. Metabolic abnormalities related to atypical antipschotics do not only lead to increase in mortality, but also worsen clinical course and functionality of patients with schizophrenia. Thus, patients treated with atypical antipsychotics should be evaluated routinely with respect to their metabolic states. In this article, metabolic side effects of atypical antipsychotics and their mechanisms were investigated on pharmacological basis.
Schizophrenia; Metabolic syndrome; Atypical antipsychotics